Brazilian experts' consensus on the treatment of infantile epileptic spasm syndrome in infants

Letícia Pereira de Brito Sampaio1, Adélia Maria de Miranda Henriques-Souza2,3, Mariana Ribeiro Marcondes da Silveira1

  • 1Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, São Paulo SP, Brazil.

PubMed

Insights

Early treatment of Infantile Epileptic Spasms Syndrome (IESS) with accessible medications like oral prednisolone and vigabatrin is feasible and effective. Standardized protocols improve outcomes and reduce relapses in children with this severe neurological disorder.

Area of Science:

  • Pediatric Neurology
  • Epileptology
  • Clinical Therapeutics

Background:

  • Infantile Epileptic Spasms Syndrome (IESS) is a severe early-onset condition often linked to brain disorders, leading to psychomotor decline and adult epilepsy.
  • Treatment for IESS is challenging due to medication resistance and frequent relapses.

Purpose of the Study:

  • To review the literature on IESS treatment strategies.
  • To offer practical guidance for healthcare systems with limited resources, focusing on available therapies.

Main Methods:

  • An expert committee from the Brazilian Society of Child Neurology conducted a review of scientific evidence.
  • Focus was placed on treatments for IESS that are accessible within Brazil.

Main Results:

  • Oral prednisolone and vigabatrin are recommended first-line therapies due to efficacy and availability in Brazil's public health system.
  • Intramuscular ACTH shows similar efficacy but is not available; other antiseizure drugs have limited response.
  • Ketogenic diet and epilepsy surgery are options for refractory cases.

Conclusions:

  • Early IESS treatment using effective and available drugs is achievable in resource-limited settings.
  • Implementing standard treatment protocols can lead to faster cessation of spasms and fewer relapses.
Abstract

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
322
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
384
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
393
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
198
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
430
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
50